Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
50 Pages - GMD12092
$1,500.00

Summary

Global Markets Direct’s, ‘Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2014’, provides an overview of the Idera Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Idera Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Idera Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Idera Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Idera Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Idera Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Idera Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Idera Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Idera Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Idera Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Idera Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Idera Pharmaceuticals, Inc. Snapshot 5
Idera Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Idera Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Idera Pharmaceuticals, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Idera Pharmaceuticals, Inc. - Pipeline Products Glance 13
Idera Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Idera Pharmaceuticals, Inc. - Early Stage Pipeline Products 15
IND/CTA Filed Products/Combination Treatment Modalities 15
Preclinical Products/Combination Treatment Modalities 16
Idera Pharmaceuticals, Inc. - Drug Profiles 17
IMO-3100 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
IMO-8400 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
IMO-2055 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
GSO Compunds 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
IMO-4200 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
IMO-9200 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
TLR3 Agonist 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Idera Pharmaceuticals, Inc. - Pipeline Analysis 28
Idera Pharmaceuticals, Inc. - Pipeline Products by Target 28
Idera Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 30
Idera Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 31
Idera Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 32
Idera Pharmaceuticals, Inc. - Recent Pipeline Updates 34
Idera Pharmaceuticals, Inc. - Dormant Projects 41
Idera Pharmaceuticals, Inc. - Discontinued Pipeline Products 42
Discontinued Pipeline Product Profiles 42
IMO-2055 42
IMO-2125 42
Idera Pharmaceuticals, Inc. - Company Statement 43
Idera Pharmaceuticals, Inc. - Locations And Subsidiaries 48
Head Office 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables
Idera Pharmaceuticals, Inc., Key Information 5
Idera Pharmaceuticals, Inc., Key Facts 5
Idera Pharmaceuticals, Inc. - Pipeline by Indication, 2014 7
Idera Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Idera Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Idera Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 11
Idera Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Idera Pharmaceuticals, Inc. - Phase II, 2014 13
Idera Pharmaceuticals, Inc. - Phase I, 2014 14
Idera Pharmaceuticals, Inc. - IND/CTA Filed, 2014 15
Idera Pharmaceuticals, Inc. - Preclinical, 2014 16
Idera Pharmaceuticals, Inc. - Pipeline by Target, 2014 29
Idera Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 30
Idera Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 31
Idera Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 33
Idera Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 34
Idera Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 41
Idera Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 42

List of Figures
Idera Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2014 7
Idera Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9
Idera Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10
Idera Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2014 28
Idera Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2014 30
Idera Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2014 31
Idera Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 32

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax